{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:59:29Z","timestamp":1788577169308,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>We investigated the association of high-sensitivity cardiac troponin (Hs-cTn) with all-cause and cardiovascular mortality in non-diabetic individuals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included 10,393 participants without known diabetes and cardiovascular disease from the US National Health and Nutrition Examination Survey (NHANES). Serum Hs-cTnI and Hs-cTnT concentrations were measured. Prediabetes was defined as fasting blood glucose between 100 and 125\u00a0mg\/dL or HbA1c between 5.7 and 6.4%. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality risk. Time-dependent receiver operating characteristics (tROC) curves were utilized to measure the predictive performance of the biomarkers. Net Reclassification Improvement (NRI) were calculated to estimate the improvement in risk classification for adding Hs-cTnT or Hs-cTnI to the standard models based on Framingham risk factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean age of the participants was 48.1\u2009\u00b1\u200919.1 years, with 53.3% being female and 25.8% being prediabetic. After multivariable adjustment, compared to those with Hs-cTnI concentration less than the limit of detection, the HRs (95% CIs) of the participants with Hs-cTnI concentration higher than the 99th upper reference limit were 1.74 (1.35, 2.24) for all-cause mortality and 2.10 (1.36, 3.24) for cardiovascular mortality. The corresponding HRs (95% CIs) for Hs-cTnT were 2.07 (1.53, 2.81) and 2.92 (1.47, 5.80) for all-cause and cardiovascular mortality. There was a significant interaction between prediabetes and Hs-cTnI on the mortality risk; a positive relationship was only observed in prediabetic individuals. No interaction was observed between prediabetes and Hs-cTnT on mortality risk. The Areas Under tROC indicated both Hs-cTnT and Hs-cTnI show better predictive performance in cardiovascular mortality than in all-cause mortality. NRI (95% CI) for adding Hs-cTnT to the standard model were 0.25 (0.21, 0.27) and 0.33 (0.26, 0.39) for all-cause and cardiovascular mortality. The corresponding NRI (95% CI) for Hs-cTnI were 0.04 (0, 0.06) and 0.07 (0.01, 0.13).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Elevated blood levels of Hs-cTnI and Hs-cTnT are associated with increased mortality. Measurement of Hs-cTnT in non-diabetic subjects, particularly those with prediabetes, may help identify individuals at an increased risk of cardiovascular disease and provide early and more intensive risk factor modification.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-02003-2","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T18:05:02Z","timestamp":1698689102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Association between high sensitivity cardiac troponin and mortality risk in the non-diabetic population: findings from the National Health and Nutrition Examination Survey"],"prefix":"10.1186","volume":"22","author":[{"given":"Lin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Ting","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M. Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"2003_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ecl.2017.10.001","volume":"47","author":"B Brannick","year":"2018","unstructured":"Brannick B, Dagogo-Jack S. Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and risk reduction. Endocrinol Metab Clin North Am. 2018;47:33\u201350.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2003_CR2","unstructured":"National diabetes statistics report, 2020. Atlanta GA: Centers for disease control and prevention, U.S. dept of health and human services. 2020."},{"key":"2003_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jama.2021.10403","volume":"326","author":"DE Jonas","year":"2021","unstructured":"Jonas DE, Crotty K, Yun JDY, et al. Screening for prediabetes and type 2 diabetes: updated evidence report and systematic review for the US preventive services task force. JAMA. 2021;326:744\u201360.","journal-title":"JAMA"},{"key":"2003_CR4","first-page":"e368","volume":"144","author":"M Gulati","year":"2021","unstructured":"Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR guideline for the evaluation and diagnosis of chest pain: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation. 2021;144:e368\u2013454.","journal-title":"Circulation"},{"key":"2003_CR5","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1161\/CIRCULATIONAHA.118.038529","volume":"139","author":"P Welsh","year":"2019","unstructured":"Welsh P, Preiss D, Hayward C, et al. Cardiac troponin T and troponin I in the general population. Circulation. 2019;139:2754\u201364.","journal-title":"Circulation"},{"key":"2003_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12933-021-01365-9","volume":"20","author":"M Witkowski","year":"2021","unstructured":"Witkowski M, Wu Y, Hazen SL, et al. Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes. Cardiovasc Diabetol. 2021;20:171.","journal-title":"Cardiovasc Diabetol"},{"key":"2003_CR7","first-page":"1","volume":"2","author":"CL Johnson","year":"2013","unstructured":"Johnson CL, Paulose-Ram R, Ogden CL, et al. National health and nutrition examination survey: analytic guidelines, 1999\u20132010. Vital Health Stat. 2013;2:1\u201324.","journal-title":"Vital Health Stat"},{"issue":"Suppl 1","key":"2003_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2337\/dc10-S011","volume":"33","author":"American Diabetes A","year":"2010","unstructured":"American Diabetes A. Standards of medical care in diabetes\u20132010. Diabetes Care. 2010;33(Suppl 1):11\u201361.","journal-title":"Diabetes Care"},{"key":"2003_CR9","unstructured":"https:\/\/wwwn.cdc.gov\/Nchs\/Nhanes\/1999-2000\/SSTROP_A.htm; Accessed on Aug 30, 2023"},{"key":"2003_CR10","unstructured":"Contemporary cardiac troponin I and T assay analytical characteristics designated by manufacturer IFCC committee on clinical applications of cardiac bio-markers. https:\/\/ifcc.web.insd.dk\/media\/479434\/contemporary-cardiac-troponin-i-and-t-assay-analytical-characteristics-designated-by-manufacturer-v052022.pdf. Accessed on Aug 30, 2023"},{"key":"2003_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u201357.","journal-title":"Hypertension"},{"key":"2003_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"2003_CR13","volume-title":"NHANES laboratory\/medical technologists procedures manual","author":"CDC","year":"2001","unstructured":"CDC. NHANES laboratory\/medical technologists procedures manual. Atlanta: CDC; 2001."},{"key":"2003_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ahj.2014.10.005","volume":"169","author":"KB Filion","year":"2015","unstructured":"Filion KB, Agarwal SK, Ballantyne CM, et al. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the atherosclerosis risk in communities (ARIC) study. Am Heart J. 2015;169:31-38.e33.","journal-title":"Am Heart J"},{"key":"2003_CR15","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1161\/CIRCULATIONAHA.116.025505","volume":"135","author":"SL Seliger","year":"2017","unstructured":"Seliger SL, Hong SN, Christenson RH, et al. High-sensitive cardiac troponin T as an early biochemical signature for clinical and subclinical heart failure: MESA (multi-ethnic study of atherosclerosis). Circulation. 2017;135:1494\u2013505.","journal-title":"Circulation"},{"key":"2003_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ejhf.1359","volume":"21","author":"R Rorth","year":"2019","unstructured":"Rorth R, Jhund PS, Kristensen SL, et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019;21:40\u20139.","journal-title":"Eur J Heart Fail"},{"key":"2003_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/1354750X.2019.1606278","volume":"24","author":"Y Takahashi","year":"2019","unstructured":"Takahashi Y, Satoh M, Ohmomo H, et al. Association between high-sensitivity cardiac troponin T and future cardiovascular incidence in a general Japanese population: results from the Tohoku medical megabank project. Biomarkers. 2019;24:566\u201373.","journal-title":"Biomarkers"},{"key":"2003_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/clinchem\/hvaa288","volume":"67","author":"J Ishigami","year":"2021","unstructured":"Ishigami J, Kim Y, Sang Y, et al. High-sensitivity cardiac troponin, natriuretic peptide, and long-term risk of acute kidney injury: the atherosclerosis risk in communities (ARIC) study. Clin Chem. 2021;67:298\u2013307.","journal-title":"Clin Chem"},{"key":"2003_CR19","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1161\/CIRCULATIONAHA.110.005264","volume":"123","author":"JT Saunders","year":"2011","unstructured":"Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. Circulation. 2011;123:1367\u201376.","journal-title":"Circulation"},{"key":"2003_CR20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamacardio.2021.3187","volume":"6","author":"JD Berry","year":"2021","unstructured":"Berry JD, Nambi V, Ambrosius WT, et al. Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial. JAMA Cardiol. 2021;6:1397\u2013405.","journal-title":"JAMA Cardiol"},{"key":"2003_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023314","volume":"11","author":"SB Ascher","year":"2022","unstructured":"Ascher SB, Scherzer R, de Lemos JA, et al. Associations of high-sensitivity troponin and natriuretic peptide levels with serious adverse events in SPRINT. J Am Heart Assoc. 2022;11: e023314.","journal-title":"J Am Heart Assoc"},{"key":"2003_CR22","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1161\/CIRCULATIONAHA.110.009928","volume":"123","author":"BM Everett","year":"2011","unstructured":"Everett BM, Cook NR, Magnone MC, et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the women\u2019s health study. Circulation. 2011;123:2811\u20138.","journal-title":"Circulation"},{"key":"2003_CR23","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/1535370216654227","volume":"241","author":"B Brannick","year":"2016","unstructured":"Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood). 2016;241:1323\u201331.","journal-title":"Exp Biol Med (Maywood)"},{"key":"2003_CR24","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2337\/dc14-0396","volume":"37","author":"PA Halban","year":"2014","unstructured":"Halban PA, Polonsky KS, Bowden DW, et al. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care. 2014;37:1751\u20138.","journal-title":"Diabetes Care"},{"key":"2003_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-20","volume":"12","author":"G Papa","year":"2013","unstructured":"Papa G, Degano C, Iurato MP, et al. Macrovascular complication phenotypes in type 2 diabetic patients. Cardiovasc Diabetol. 2013;12: 20.","journal-title":"Cardiovasc Diabetol"},{"key":"2003_CR26","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1210\/jc.2008-1348","volume":"94","author":"S Dagogo-Jack","year":"2009","unstructured":"Dagogo-Jack S, Askari H, Tykodi G. Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose. J Clin Endocrinol Metab. 2009;94:2031\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"2003_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1177\/2048872617748553","volume":"7","author":"J Mair","year":"2018","unstructured":"Mair J, Lindahl B, Hammarsten O, et al. How is cardiac troponin released from injured myocardium? Eur Heart J Acute Cardiovasc Care. 2018;7:553\u201360.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2003_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2337\/dc16-1541","volume":"40","author":"SP Whelton","year":"2017","unstructured":"Whelton SP, McEvoy JW, Lazo M, et al. High-sensitivity cardiac troponin T (hs-cTnT) as a predictor of incident diabetes in the atherosclerosis risk in communities study. Diabetes Care. 2017;40:261\u20139.","journal-title":"Diabetes Care"},{"key":"2003_CR29","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"G Study","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes, Study G, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"2003_CR30","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.jacc.2016.10.020","volume":"68","author":"I Ford","year":"2016","unstructured":"Ford I, Shah AS, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol. 2016;68:2719\u201328.","journal-title":"J Am Coll Cardiol."},{"key":"2003_CR31","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2337\/dc09-9033","volume":"32","author":"C International Expert","year":"2009","unstructured":"International Expert C. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327\u201334.","journal-title":"Diabetes Care"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-02003-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T18:05:45Z","timestamp":1698689145000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-02003-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2003"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-02003-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"21 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey protocol was approved by the Research Ethics Review Board of the National Center for Health Statistics (), and NHANES has obtained written informed consent from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}